Radiosurgery and Avastin for Recurrent Malignant Gliomas

Status: Completed
Location: See location...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No
View:

• History of malignant glioma (WHO Grade III or IV) of the brain treated with some combination of surgery, biochemotherapy and conventionally fractionated external beam radiotherapy

• Radiotherapy completed at least 6 months prior to recurrence

• Age 18 years and older

• New or enlarging contrast-enhancing and/or 18FDG-avid nodule, at least 1 cm diameter

• Estimated life expectancy of 3 months or longer

Locations
United States
North Carolina
Duke University Medical Center, Radiation Oncology
Durham
Time Frame
Start Date: December 2009
Completion Date: February 2012
Participants
Target number of participants: 15
Treatments
Experimental: Stereotactic Radiosurgery
Avastin and Radiosurgery
Related Therapeutic Areas
Sponsors
Collaborators: Genentech, Inc.
Leads: Duke University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials